Literature DB >> 10099092

Dose selection in stereotactic radiosurgery.

J C Flickinger1, D Kondziolka, L D Lunsford.   

Abstract

Selection of the prescription dose for radiosurgery is the final step in treatment planning. Dose selection should take into account the expectation of treatment success (i.e., tumor control, arteriovenous malformation [AVM] obliteration, and so forth) and complication risks at various doses. Accurately predicting complication risks for individual patients is a complex process that is highly dependent on the radiosurgery treatment volume, the target location, and the nature of the target tissue. Dose-response data for desired outcomes of radiosurgery are sparse and difficult to interpret for most indications, with perhaps the exception of AVM obliteration. This article reviews the principles governing dose-selection and the evolving body of data guiding dose selection in radiosurgery.

Entities:  

Mesh:

Year:  1999        PMID: 10099092

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  4 in total

Review 1.  Long term experience of gamma knife radiosurgery for benign skull base meningiomas.

Authors:  W Kreil; J Luggin; I Fuchs; V Weigl; S Eustacchio; G Papaefthymiou
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

2.  [Stereotactic radiosurgery and fractionated stereotactic radiotherapy of acoustic neuromas].

Authors:  F Unger; K Dominikus; K Haselsberger
Journal:  HNO       Date:  2011-01       Impact factor: 1.284

3.  Multisession stereotactic radiosurgery for large benign brain tumors of >3cm- early clinical outcomes.

Authors:  Azhar Rashid; Muhammad Ali Memon; Usman Ahmed; Muhammad Abid Saleem; Amer Iqtidar Bhatti; Naveed Ahmed; Abdul Sattar M Hashim
Journal:  J Radiosurg SBRT       Date:  2012

4.  Simulation of intrafraction motion and overall geometrical accuracy of a frameless intracranial radiosurgery process.

Authors:  Vladimir Feygelman; Luke Walker; Prakash Chinnaiyan; Kenneth Forster
Journal:  J Appl Clin Med Phys       Date:  2008-10-24       Impact factor: 2.102

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.